SEC Form 3 
FORM 3	UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 	  
OMB APPROVAL
OMB Number:	3235-0104	
Estimated average burden	
hours per response:	0.5	

	
1. Name and Address of Reporting Person*
Delphi Management Partners VIII, L.L.C.	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD,	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	2. Date of Event Requiring Statement (Month/Day/Year)
11/13/2013 	3. Issuer Name and Ticker or Trading Symbol 
TANDEM DIABETES CARE INC [ TNDM ] 		
		4. Relationship of Reporting Person(s) to Issuer 
(Check all applicable) 
	Director	X	10% Owner	
	Officer (give title below)		Other (specify below)	
	
	5. If Amendment, Date of Original Filed (Month/Day/Year)				
			6. Individual or Joint/Group Filing (Check Applicable Line) 
	Form filed by One Reporting Person	
X	Form filed by More than One Reporting Person	
	
Table I - Non-Derivative Securities Beneficially Owned	
1. Title of Security (Instr. 4) 	2. Amount of Securities Beneficially Owned (Instr. 4) 	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 	4. Nature of Indirect Beneficial Ownership (Instr. 5) 	
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities) 	
1. Title of Derivative Security (Instr. 4) 	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 	4. Conversion or Exercise Price of Derivative Security 	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 	6. Nature of Indirect Beneficial Ownership (Instr. 5) 	
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series C Preferred Stock	(1) 	(2) 	Common Stock	664,565	0.00	I	See footnote(3) 	
Series C Preferred Stock	(1) 	(2) 	Common Stock	6,488	0.00	I	See footnote(4) 	
Series D Preferred Stock	(1) 	(2) 	Common Stock	2,967,987	0.00	I	See footnote(3) 	
Series D Preferred Stock	(1) 	(2) 	Common Stock	28,979	0.00	I	See footnote(4) 	
1. Name and Address of Reporting Person*
Delphi Management Partners VIII, L.L.C.	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD,	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
DELPHI VENTURES VIII LP	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
Delphi BioInvestments VIII LP	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
ROEDER DOUGLAS A	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
BOCHNOWSKI JAMES J	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
DOUGLASS DAVID L	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
1. Name and Address of Reporting Person*
PAKIANATHAN DEEPIKA	

(Last)	(First)	(Middle)	
3000 SAND HILL ROAD	
BUILDING 1, SUITE 135	

(Street) 
MENLO PARK	CA	94025	

(City)	(State)	(Zip)	
	
Explanation of Responses:	
1. The securities are immediately convertible.	
2. The expiration date is not relevant to the conversion of these securities.	
3. The reported securities are owned directly by Delphi Ventures VIII, L.P. ("DV VIII"). Delphi Management Partners VIII, L.L.C. (the "General Partner"), as general partner of Delphi Ventures VIII, L.P., and Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D., the managing members of the General Partner, may be deemed to share voting and dispositive power over the reported securities but each disclaims beneficial ownership in the securities held by DV VIII, except to the extent of their pecuniary interest therein.	
4. The reported securities are owned directly by Delphi BioInvestments VIII, L.P. ("DBI VIII"). The General Partner, as general partner of Delphi BioInvestments VIII, L.P., and Douglas A. Roeder, James J. Bochnowski, David L. Douglass and Deepika R. Pakianathan, Ph.D., the managing members of the General Partner, may be deemed to share voting and dispositive power over the reported securities but each disclaims beneficial ownership in the securities held by DBI VIII, except to the extent of their pecuniary interest therein.	
Remarks:	
	
	/s/ David B. Berger, Attorney-in-Fact for Delphi Management Partners VIII, L.L.C.	11/13/2013	
	/s/ David B. Berger, Attorney-in-Fact for Delphi Ventures VIII, L.P.	11/13/2013	
	/s/ David B. Berger, Attorney-in-Fact for Delphi BioInvestments VIII, L.P.	11/13/2013	
	/s/ David B. Berger, Attorney-in-Fact for Douglas A. Roeder	11/13/2013	
	/s/ David B. Berger, Attorney-in-Fact for James T. Bochnowski	11/13/2013	
	/s/ David B. Berger, Attorney-in-Fact for David L. Douglass	11/13/2013	
	/s/ David B. Berger, Attorney-in-Fact for Deepika R. Pakianathan	11/13/2013	
	** Signature of Reporting Person	Date	
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.	
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).	
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).	
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.	
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.	
POWER OF ATTORNEY
        The undersigned hereby constitutes and appoints David B. Berger, John Cajigas,
Leigh Vosseller and Bruce Feuchter, or any of them signing individually, the
undersigned's true and lawful attorney-in-fact to:
(1)     execute for and on behalf of the undersigned, in the undersigned's capacity
as the beneficial owner of more than ten percent (10.0%) of any class of any
equity security of Tandem Diabetes Care, Inc. (the "Company"), Forms 3, 4 and 5
in accordance with Section 16(a) of the Securities Exchange Act of 1934, as
amended (the "Exchange Act") and the rules and regulations thereunder;
(2)     do and perform any and all acts for and on behalf of the undersigned that
may be necessary or desirable to complete and execute any such Forms 3, 4s and
5s and timely file such form with the SEC and any stock exchange or similar
authority; and
(3)     take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of benefit to,
in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.
        The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform each and every act and thing whatsoever requisite,
necessary or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution and revocation,
hereby ratifying and confirming all that each such attorney-in-fact, or each
such attorney-in-fact's substitute or substitutes, shall lawfully do or cause to
be done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that each of the foregoing
attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 of the Exchange Act.
        The undersigned agrees that each such attorney-in-fact may rely entirely on
information furnished orally or in writing by the undersigned to each such
attorney-in-fact.  The undersigned also agrees to indemnify and hold harmless
the Company and each such attorney-in-fact against any losses, claims, damages
or liabilities (or actions in these respects) that arise out of or are based on
any untrue statement or omission of necessary facts in the information provided
by the undersigned to such attorney-in-fact for purposes of executing,
acknowledging, delivering and filing Forms 3, 4s or 5s (including amendments
thereto) and agrees to reimburse the Company and each such attorney-in-fact for
any legal or other expenses reasonably incurred in connection with investigating
or defending against any such loss, claim, damage, liability or action.
        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4s and 5s with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

        IN WITNESS WHEREOF, the undersigned have caused this Power of Attorney to be
executed as of this 11th day of November 2013.

DELPHI VENTURES VIII, L.P.
By: Delphi Management Partners VIII, LLC
It:   General Partner
/s/ Douglas A. Roeder, Managing Member

DELPHI BIOINVESTMENTS VIII, L.P.
By: Delphi Management Partners VIII, LLC
It:   General Partner
/s/ Douglas A. Roeder, Managing Member

/s/ Douglas A. Roeder, an individual

/s/ James J. Bochnowski, an individual

/s/ David L. Douglass, an individual

/s/ Deepika R. Pakianathan, Ph. D, an individual

DELPHI MANAGEMENT PARTNERS VIII, LLC
/s/ Douglas A. Roeder, Managing Member